ProteoNic Licenses Protein Expression Technology to Gilead Sciences

November 6, 2020
Pharmaceutical Technology Editors

ProteoNic has licensed its protein expression technology, 2G UNic, to Gilead Sciences.

Technology and services provider, ProteoNic, has licensed its protein expression technology, 2G UNic, to Gilead Sciences, it was announced in a Nov. 5, 2020 press release. Financial details were not disclosed.

The protein expression technology works by improving production levels across a range of mammalian host cells and selection systems. The technology can be applied to all relevant protein classes and can be combined with other protein expression-enhancing technologies. Under the terms of the licensing agreement, Gilead will obtain non-exclusive commercial rights for the application of 2G UNic to the development of its proprietary products from mammalian cells.

“We are pleased that we can play a role in the production of Gilead’s therapeutic proteins,” said Frank Pieper, CEO of ProteoNic, in the press release. “ProteoNic’s clients consistently achieve strongly increased cell line productivity and reduced manufacturing cost in the production of their biologics. We will continue our work towards reaching the maximum production potential for our clients.”

Source: ProteoNic